Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates

David‐Dan Nguyen; Neil Barber; Mo Bidair; Peter Gilling; Paul Anderson; Kevin C. Zorn; Gopal Badlani; Mitch Humphreys; Steven A. Kaplan; Ronald P. Kaufman; Alan So; Ryan F. Paterson; Larry Goldenberg; Dean Elterman; Mihir Desai; J.E. Lingeman; Claus G. Roehrborn; Naeem Bhojani

doi:10.1111/bju.14917

Abstract

Aquablation clinically normalises outcomes between patients with 30-80 mL prostates and patients with 80-150 mL prostates treated for LUTS/BPH, with an expected increase in the risk of complications in larger prostates. Long-term outcomes of procedure durability are needed.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nguyen et al. (2019) studied this question.

synapsesocial.com/papers/69d953ef00ab073a27836215 https://doi.org/10.1111/bju.14917

View Full Paper

Ask AI

Bookmark

Share

Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates

Abstract

Discussion

Cite This Study

Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates

Abstract

Discussion

Cite This Study

Keep reading

Keep reading